Analysis of Biotech Stocks: Moderna and CRISPR Insights

Investors are being urged to consider biotech stocks like Moderna and CRISPR Therapeutics for potential growth. As the pandemic wanes, Moderna's innovative pipeline may pave the way for future revenue streams, while CRISPR's recent approval supports its market position.

Date: 20-03-2025

AI Rating: 6

Investing in Biotech: The Potential Dynamics

The report highlights two prominent biotech companies: Moderna and CRISPR Therapeutics. Both companies are in unique situations that could influence stock prices.

Moderna's Position

Moderna (NASDAQ: MRNA) experienced a significant drop of nearly 80% in stock price over the past three years. This decline follows a peak revenue of over $18 billion in 2022 from its coronavirus vaccine. Although its revenue from this product is expected to decrease, the report emphasizes Moderna's pipeline that includes late-stage products, which could potentially unlock new revenue streams. Having over $9 billion in cash indicates strong financial backing for its development efforts. If Moderna secures regulatory approvals for its candidates, it may stimulate stock price growth in the future.

CRISPR Therapeutics Insights

CRISPR Therapeutics (NASDAQ: CRSP) recently celebrated the approval of its product, Casgevy, which represents a notable achievement in gene-editing technology. While the stock did face a decline of nearly 40% in 2024 following commercialization, the company's financial position, supported by $1.9 billion in cash, offers room for further product development. The anticipated updates from ongoing studies may serve as catalysts for future stock performance.

In summary, investors looking at these biotech stocks need to be patient and consider the long-term potential and upcoming milestones, particularly related to product approvals and revenue generation.

Stocks: MRNA CRSP